Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Eli Lilly (NYSE: LLY) has been growing its sales ... Zepbound is administered via subcutaneous injection once a week. However, some patients don't like to poke needles into their skin and would ...

Eli Lilly (LLY) announced Thursday that its daily ... for diabetes and weight loss — both of which are administered by injection. Orforglipron is the first small-molecule GLP-1 taken without ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, Wegovy, Mounjaro and Zepbound, the pharmaceuticals giant said Thursday.

The level of weight loss was similar to that achieved over the same period with Novo Nordisk’s injection but slightly lower than that with Eli Lilly’s injection in unrelated trials.

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

Novo Nordisk and Eli Lilly currently dominate the weight-loss market, but their drugs are administered by injection. Both are working on pill versions that are seen as more convenient for patients ...